Skip to main content
Clinical Trials/NL-OMON44516
NL-OMON44516
Recruiting
Not Applicable

Molecular studies on reduced ovarian reserve and embryo competence in BRCA1/2 mutation carriers - BRCA1/2, ovarian reserve and embryo competence (ORCA)

Medisch Universitair Ziekenhuis Maastricht0 sites104 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
hereditary breast cancer
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
104
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • \-IVF/PGD treatment for a BRCA1/2\-mutation, both male and female mutation carriers (Control group A and Test group, respectively)
  • \-IVF/PGD treatment because the male partner has an autosomal dominant hereditary disorder (such as but not restricted to Huntingtons disease or Marfan syndrome) or both male/female partners carry a autosomal recessive hereditary disorder (such as but not restricted to cystic fibrosis or spinal muscular atrophy )(Control group B)

Exclusion Criteria

  • \- Known hereditary disease other than due to BRCA1/2\-mutations in the female
  • \- Known genetic abnormalities in female leading to diminished ovarian reserve: carriers of fragile X syndrome or abnormalities of the X\-chromosome
  • \- Hereditary disease in male known to affect embryo development
  • \- Known history of a malignancy in the female
  • \- Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or renal)
  • \- History of cancer treatment in the female or male
  • \- Non\-Dutch couples, not able to understand the patient information to give informed consent properly

Outcomes

Primary Outcomes

Not specified

Similar Trials